Component: (Network and Table)
Network
00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS
(http://www.endocyte.com/role/StatementCondensedConsolidatedBalanceSheets)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001235007 (http://www.sec.gov/CIK)
Statement Of Financial Position [Abstract]Period [Axis]
2016-12-31
2015-12-31
Statement Of Financial Position [Abstract]
 
 
Assets
 
 
Current assets:
 
 
Cash and cash equivalents
31,228,192  
15,431,622  
Short-term investments
106,979,224  
158,168,832  
Receivables
55,074  
8,678  
Prepaid expenses
1,737,308  
772,579  
Other assets
255,912  
493,863  
Total current assets
140,255,710  
 
174,875,574  
 
Property and equipment, net
3,205,077  
3,398,398  
Other noncurrent assets
33,567  
111,605  
Total assets
143,494,354  
 
178,385,577  
 
Liabilities and Stockholders’ Equity
 
 
Current liabilities:
 
 
Accounts payable
1,381,545  
1,262,565  
Accrued wages and benefits
2,705,475  
3,272,237  
Accrued clinical trial expenses
861,293  
804,066  
Accrued expenses and other liabilities
613,861  
850,125  
Total current liabilities
5,562,174  
 
6,188,993  
 
Other liabilities, net of current portion
2,873  
18,503  
Deferred revenue, net of current portion
781,944  
831,944  
Total liabilities
6,346,991  
 
7,039,440  
 
Stockholders’ equity:
 
 
Common stock: $0.001 par value, 100,000,000 shares authorized; 42,034,733 and 42,377,522 shares issued and outstanding at December 31, 2015 and December 31, 2016
42,378  
42,035  
Additional paid-in capital
390,768,742  
381,118,489  
Accumulated other comprehensive (loss) income
(41,196) 
(79,399) 
Retained deficit
(253,622,561) 
(209,734,988) 
Total stockholders’ equity
137,147,363  
 
171,346,137  
 
Total liabilities and stockholders’ equity
143,494,354  
 
178,385,577